ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
AdvisorShares Psychedelics ETF
24.45
-0.6750
-2.69%
成交量：
4.84萬
成交額：
118.04萬
市值：
5,671.18萬
市盈率：
- -
高：
25.32
開：
25.32
低：
24.14
收：
25.12
52周最高：
27.02
52周最低：
15.63
股本：
232.00萬
流通股本：
232.00萬
量比：
1.27
換手率：
2.09%
股息：
1.70
股息率：
6.97%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
Compass Pathways在2026年精神病學大會上於美國啓動‘改變難治性抑鬱症的旋律’項目，深化醫療專業人士認知
美股速递
·
昨天
專家敦促美國食品藥品監督管理局（FDA）為迷幻藥物制定明確的安全和獲取標準
路透中文
·
昨天
Compass Pathways公布美國資助計劃入選者，旨在推進Comp360獲批後供應商培訓項目
美股速递
·
09/10
Compass Pathways 25毫克組在第52周實現MADRS平均降低13點，療效持續至一年
美股速递
·
09/09
Compass Pathways：Comp360在C部分的安防特性與此前階段保持一致，無新增安全性發現
美股速递
·
09/09
Compass Pathways發布COMP005三期試驗52周開放標籤頂線數據：Part C部分追加COMP360劑量，療效持久性延長至一年
美股速递
·
09/09
《柳葉刀·神經病學》刊發阿爾凱默斯Alixorexton治療1型發作性睡病II期臨床積極數據
美股速递
·
08/25
NRX Pharmaceuticals（納斯達克：NRXP）發布2026年第二季度財務業績並更新公司動態；電話會議定於8月17日（周一）美東時間下午4：30召開
美股速递
·
08/17
美銀證券：中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價
新浪港股
·
08/13
NRX Pharmaceuticals迎來轉機：FDA將在2026年8月6日會議後以最快周期審核認證
美股速递
·
08/07
Compass Pathways攜手美國退伍軍人事務部，推進裸蓋菇素臨床研究
美股速递
·
08/06
NRX Pharmaceuticals - 7月21日，NRXD獲DARPA選中，就潛在SPARC-TMS臨床試驗資助進行談判 - SEC文件披露
美股速递
·
07/22
阿爾凱默斯Alixorexton長期擴展研究中期分析顯示：對1型與2型發作性睡病成人患者日間覺醒維持改善效果
美股速递
·
07/13
阿爾凱默斯 - Alixorexton在首次給藥九個月後，於第24周在MWT和ESS上顯示出持續改善
美股速递
·
07/13
阿爾凱默斯與安尼爾終止授權仿製藥供應協議
美股速递
·
07/08
阿爾凱默斯與安尼爾協議終止後，無需承擔罰金或額外義務——SEC文件披露
美股速递
·
07/08
BUZZ——美國股市動態-特斯拉、英偉達、Rivian
路透中文
·
07/07
COMPASS Pathways股價盤前大漲8.6%，抑鬱症療法後期試驗數據積極
美股速递
·
07/07
COMPASS Pathways公布第二階段三期試驗六個月數據，證實快速且持久的療效特徵
美股速递
·
07/07
COMPASS Pathways旗下COMP360持續展現良好耐受性與安全性，未發現新安全風險
美股速递
·
07/07
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/PSIL/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.445,"timestamp":1789498653317,"preClose":25.12,"halted":0,"volume":48406,"delay":0,"changeRate":-0.026871019108280284,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"交易中","change":-0.675,"latestTime":"09-15 14:58:57 EDT","open":25.3215,"high":25.3215,"low":24.14,"amount":1180413.22608,"amplitude":0.047034,"askPrice":24.66,"askSize":1000,"bidPrice":24.17,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":25.12,"sharesOutstanding":1184976,"nav":24.85,"aum":57650992.8,"dividendRate":0.069671,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.12,"preClose":25.12,"latestTime":"19:30 EDT","volume":167,"amount":4194.275,"timestamp":1789428602004,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.270761,"impliedVol":0.495,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.270761,"shares":2319976,"dividePrice":1.7031,"high":25.3215,"amplitude":0.047034,"preClose":25.12,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.445,"committee":-0.818182,"eps":0,"divideRate":0.069671,"volume":48406,"delay":0,"ttmEps":0,"open":25.3215,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.96,"twentyDayClose":25.83,"sixtyDayClose":20.0904},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111501056","title":"Compass Pathways在2026年精神病學大會上於美國啓動‘改變難治性抑鬱症的旋律’項目，深化醫療專業人士認知","url":"https://stock-news.laohu8.com/highlight/detail?id=1111501056","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111501056?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:31","pubTimestamp":1789468272,"startTime":"0","endTime":"0","summary":"在即将召开的2026年精神病学大会上，COMPASS Pathways plc正式宣布于美国市场推出全新倡议——“改变难治性抑郁症的旋律”。该项目的核心目标在于拓宽医疗保健专业人士对难治性抑郁症的理解边界，推动临床认知的迭代升级。在2026年精神病学大会这一汇聚全球精神健康领域顶尖专家的平台上，该项目无疑将占据重要位置。COMPASS Pathways此举，也标志着其在推动精神健康治疗创新道路上迈出了坚实一步，超越了药物研发本身，深入到医疗生态系统的神经中枢。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667962699","title":"專家敦促美國食品藥品監督管理局（FDA）為迷幻藥物制定明確的安全和獲取標準","url":"https://stock-news.laohu8.com/highlight/detail?id=2667962699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667962699?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 06:39","pubTimestamp":1789425555,"startTime":"0","endTime":"0","summary":"此次听证会是美国总统唐纳德·特朗普政府自4月 以来，为推动合格的迷幻药物项目 进入市场所开展的、历时数月的最新举措。发言者敦促研究人员收集有关月经周期、妊娠及产后状况、围绝经期、绝经期、激素水平及合并用药的数据，并警告称汇总结果可能会掩盖疗效或不良事件方面的差异。“FDA对安全性和有效性的评估……必须始终是未来任何临床应用的基础，”美国精神病学协会表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4S4561NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX","PSIL","BK4139","CMPS","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100081863","title":"Compass Pathways公布美國資助計劃入選者，旨在推進Comp360獲批後供應商培訓項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1100081863","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100081863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:36","pubTimestamp":1789036568,"startTime":"0","endTime":"0","summary":"Compass Pathways正式揭晓了美国资助计划的获选名单。这项计划聚焦于Comp360产品在获得监管批准之后的供应商培训事宜。通过这一举措，公司希望为相关培训体系的搭建提供有力支持。入选的机构将在后续阶段发挥关键作用，协助推动培训内容的开发与实施。此次公布的名单标志着该计划进入实质性推进阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168737220","title":"Compass Pathways 25毫克組在第52周實現MADRS平均降低13點，療效持續至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1168737220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168737220?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:36","pubTimestamp":1788950183,"startTime":"0","endTime":"0","summary":"Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅，且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性，也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161980382","title":"Compass Pathways：Comp360在C部分的安防特性與此前階段保持一致，無新增安全性發現","url":"https://stock-news.laohu8.com/highlight/detail?id=1161980382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161980382?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:33","pubTimestamp":1788950025,"startTime":"0","endTime":"0","summary":"Compass Pathways宣布，其核心候选药物Comp360在临床试验C部分的安防特性与此前的试验阶段呈现一致性，未观察到新的安全性问题。这一发现为药物的后续研发推进提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195512633","title":"Compass Pathways發布COMP005三期試驗52周開放標籤頂線數據：Part C部分追加COMP360劑量，療效持久性延長至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1195512633","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195512633?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:31","pubTimestamp":1788949897,"startTime":"0","endTime":"0","summary":"COMPASS Pathways公司近日公布了其三期临床试验COMP005的52周开放标签顶线数据。结果显示，在Part C阶段，受试者接受额外一剂COMP360治疗后，疗效持续时间得以显著延伸——长达整整一年之久。COMPASS Pathways 此前已多次强调，COMP360 的长期疗效管理是其临床开发战略的核心关注点之一。业内分析人士指出，尽管开放标签数据在证据等级上不及随机对照试验，但长期随访数据对于注册审评及临床实践指导同样不可或缺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141245521","title":"《柳葉刀·神經病學》刊發阿爾凱默斯Alixorexton治療1型發作性睡病II期臨床積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141245521?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 06:31","pubTimestamp":1787610670,"startTime":"0","endTime":"0","summary":"《柳叶刀·神经病学》杂志近日正式发表了阿尔凯默斯旗下在研药物Alixorexton的Vibrance-1 II期临床研究数据。该研究聚焦于成年1型发作性睡病患者，结果令人振奋。这项研究结果在顶级医学期刊上的亮相，标志着阿尔凯默斯在睡眠障碍治疗领域迈出了坚实一步。Alixorexton作为一种新型治疗手段，其临床数据经过了严格的同行评审，最终获得权威刊物的认可。阿尔凯默斯公司表示，这些积极数据将进一步推动Alixorexton的研发进程，有望为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","PSCH","ALKS","IBRN","BK4139","PSIL","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124751817","title":"NRX Pharmaceuticals（納斯達克：NRXP）發布2026年第二季度財務業績並更新公司動態；電話會議定於8月17日（周一）美東時間下午4：30召開","url":"https://stock-news.laohu8.com/highlight/detail?id=1124751817","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124751817?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:01","pubTimestamp":1786964479,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals（纳斯达克股票代码：NRXP）今日正式披露了截至2026年6月30日的第二季度财务报告，并同步向市场通报了公司近期运营进展。\n根据公告，该公司已敲定将于2026年8月17日（星期一）美东时间下午4：30举行投资者电话会议，届时管理层将对季度业绩进行深度解读，并就未来发展路径与市场参与者展开交流。\n此番财报发布正值公司推进关键管线项目之际，市场对其现金消耗节奏、研发里程碑达成情况以及潜在的战略合作动向均投以密切关注。NRX Pharmaceuticals在神经科学及精神健康治疗领域的布局，将持续吸引投资者审视其价值主张。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659138517","title":"美銀證券：中國CXO行業受惠生物科技融資強勁 上調藥明康德等目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=2659138517","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659138517?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 12:41","pubTimestamp":1786596060,"startTime":"0","endTime":"0","summary":"模拟交易客户端美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-13/doc-inincxku3329313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBC","CXO","SMCO","02359","SURI","FHLC","IDNA","LFSC","WX","BMED","161027","MEDI","XBIX","603259","PSIL","APXH","PSCH","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177674010","title":"NRX Pharmaceuticals迎來轉機：FDA將在2026年8月6日會議後以最快周期審核認證","url":"https://stock-news.laohu8.com/highlight/detail?id=1177674010","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177674010?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100476,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals（NRXP）迎来关键进展。美国食品药品监督管理局（FDA）已确认，将于2026年8月6日会议之后，采用最短可能的审批周期，对该公司提交的认证申请进行审查。这一安排意味着监管机构正以最高效率推进评估流程，有望大幅缩短该公司等待最终决定的漫长周期。对投资者而言，这一消息无疑为市场注入了新的变量与期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151539682","title":"Compass Pathways攜手美國退伍軍人事務部，推進裸蓋菇素臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1151539682","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151539682?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 18:43","pubTimestamp":1786012989,"startTime":"0","endTime":"0","summary":"Compass Pathways正与美国退伍军人事务部展开合作，旨在共同推进一项针对裸盖菇素的临床研究。这项实验性研究标志着在精神健康治疗领域迈出了新的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131214117","title":"NRX Pharmaceuticals - 7月21日，NRXD獲DARPA選中，就潛在SPARC-TMS臨床試驗資助進行談判 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1131214117","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131214117?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 19:09","pubTimestamp":1784718553,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. 于7月21日在提交给美国证券交易委员会的文件中披露，其已获得美国国防高级研究计划局的遴选，将就一项潜在的SPARC-TMS临床试验资助项目展开谈判。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139560681","title":"阿爾凱默斯Alixorexton長期擴展研究中期分析顯示：對1型與2型發作性睡病成人患者日間覺醒維持改善效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139560681","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139560681?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 19:03","pubTimestamp":1783940600,"startTime":"0","endTime":"0","summary":"一项长期扩展研究的中期分析数据表明，阿尔凯默斯（Alkermes PLC）旗下药物Alixorexton在治疗成人1型与2型发作性睡病患者时，能够持续改善其日间觉醒状态。该分析结果揭示了该药物在延长治疗期间维持疗效的潜力，为患者提供了长期管理症状的新希望。研究聚焦于药物对核心症状——过度日间嗜睡的持续作用，评估了患者在扩展治疗阶段保持清醒能力的变化趋势。这一积极发现进一步支持了Alixorexton作为慢性神经疾病长期治疗方案的可能性，后续完整数据值得期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","PSCH","MEDX","BK4139","PSIL","FBT","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187620650","title":"阿爾凱默斯 - Alixorexton在首次給藥九個月後，於第24周在MWT和ESS上顯示出持續改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1187620650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187620650?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 19:03","pubTimestamp":1783940597,"startTime":"0","endTime":"0","summary":"阿尔凯默斯公司宣布，其候选药物Alixorexton在首次给药九个月后，于临床试验的第24周评估中，在维持清醒测试和嗜睡量表两项关键指标上均表现出持续性的改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","IBRN","MEDX","BK4139","PSIL","PSCH","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160787890","title":"阿爾凱默斯與安尼爾終止授權仿製藥供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1160787890","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160787890?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 20:06","pubTimestamp":1783512380,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，阿尔凯默斯公司与其合作伙伴安尼尔公司已共同决定，自2026年7月6日起，终止双方此前达成的授权仿制药产品供应协议。\n这一变动标志着两家公司在该特定产品合作上的正式分道扬镳。协议的终止将影响相关仿制药未来的市场供应格局。文件披露了这一商业安排的调整，但未进一步阐述终止协议的具体原因或后续财务影响。\n市场参与者将密切关注此举对阿尔凯默斯业务管线及收入构成的潜在影响。同时，安尼尔公司的产品组合也可能因此次合作终止而面临调整。此次战略调整的长期影响，仍有待后续观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","IBRN","PSIL","BK4139","PSCH","MEDX","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155767412","title":"阿爾凱默斯與安尼爾協議終止後，無需承擔罰金或額外義務——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1155767412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155767412?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 20:06","pubTimestamp":1783512372,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的文件，阿尔凯默斯与安尼尔在协议终止后，双方均无需支付任何罚金，也无需履行进一步的义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","FBT","MEDX","BK4139","ALKS","IBRN","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982968","title":"BUZZ——美國股市動態-特斯拉、英偉達、Rivian","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982968","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982968?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:50","pubTimestamp":1783425015,"startTime":"0","endTime":"0","summary":"尽管三星交出了强劲的财报，但投资者仍在重新评估这场由人工智能驱动的涨势能否持续；与此同时，SpaceX股价在即将登陆纳斯达克100指数前出现回落。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4S4390ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QMAR","NVDS","LU1084165304.USD","IE0004445239.USD","LU0823411888.USD","LU0642271901.SGD","LU2487616109.SGD","SG9999014542.SGD","LU2505996681.GBP","LU1670628061.USD","LU0203345920.USD","SG9999015978.USD","IE00B19Z8W00.USD","WANT","LU1435385759.SGD","LU1242518931.SGD","NVDA","BK4516","BK4574","LU0069063385.USD","09366","LU2250418816.HKD","IE00BDCRKT87.USD","BK4604","IE00B19Z9P08.USD","LU2237443978.SGD","IE00BKPKM429.USD","NVDX","LU2860962120.EUR","LU2148611432.USD","IE00BN29S564.USD","LU1202635105.USD","WISE","LU2125154935.USD","NDX","IE00BJTD4V19.USD","WLDR","LU0354030511.USD","LU2552382058.USD","LU1861559042.SGD","LU0289739343.SGD","LU1691799644.USD","ANV","LU2023250330.USD","LU2125909916.SGD","LU0157215616.USD","LU1815336760.USD","LU1267930730.SGD","ABFL","RULE","LU1267930573.SGD","LU1232071149.USD","TMSL","LU0079474960.USD","PSIL","NVDW","TSLG","LU1037948897.HKD","SG9999015341.SGD","IE00B3M56506.USD","LU0823421416.USD","TSLZ","NVD3.UK","LU1035773651.USD","LU2294711713.HKD","SG9999002232.USD","LU2125154778.USD","BK4543","09766","LU2361045086.USD","LU2047632596.USD","LU0466842654.USD","LU1633808545.USD","02834","SG9999014567.USD","07388","LU1821325948.USD","IE00BD6J9T35.USD","IE00B5949003.HKD","LU2264538146.SGD","LU2746668974.SGD","GPIQ","IXN","LU0081259029.USD","LU2077746001.SGD","BK4612","LU0820562030.AUD","IE0034235188.USD","IE00B4JS1V06.HKD","LU0444971666.USD","BK4605","HK0000306701.USD","LU1989764664.SGD","LU2065169927.USD","LU0957808578.USD","IE00BMPRXN33.USD","SG9999017495.SGD","IE00BHPRN162.USD","LU0965509283.SGD","LU2092627202.USD","HK0000914686.HKD","NVDO","LU1642822529.SGD","LU2242650005.HKD","FSMD","LU2023251221.USD","07788","IE00BFSS7M15.SGD","TSLW","LU1571399168.USD","CNAV","LU1712237335.SGD","LU0861579265.USD","LU0053666078.USD","LU1069344957.HKD","NVYY","LU0225283273.USD","LU0964807845.USD","LU0061474960.USD","LU1791710582.SGD","TEST","NETG","BK4579","IE0009356076.USD","LU1992135472.HKD","LU0143551892.USD","RVNL","RIVN","SNXX","IE00BWXC8680.SGD","LU0175139822.USD","BK4554","LU1720051108.HKD","LU0234572021.USD","LU0158827948.USD","IE0003U64NQ7.SGD","LU2065170008.USD","LU0965509101.SGD","LU2097344357.USD","LU2637965513.SGD","SNDG","BK4596","LU2213496289.HKD","IE0004086264.USD","LU2491050071.SGD","LU0823414478.USD","LU2931357623.SGD","BK4503","LU2357125470.USD","LU2242649171.HKD","SG9999015952.SGD","LU1868837136.USD","LU0823434740.USD","IE00B19Z8X17.USD","LU2413666699.HKD","BK4529","LU0054578231.USD","LU0097036916.USD","LU0170899867.USD","IE00B1XK9C88.USD","IE00BZ199S13.USD","LU0345769631.USD","CRSH","LU0265550946.USD","LU0070217475.USD","LU2602419157.SGD","LU0476273544.USD","LU1153585028.USD","FDRV","IE00BJJMRX11.SGD","QQQA","BK4551","LU2360032135.SGD","LU0979878070.USD","LU1861220033.SGD","LU1861215975.USD","LU2456880835.USD","IE00B4YYXB79.USD","LU0786609619.USD","LU2125909247.SGD","HK0000532082.HKD","LU0210528500.USD","IE00B19Z9505.USD","NVDS.UK","IE00BJTD4N35.SGD","OPTZ","CGGO","DIPS","TSYY","LU0689472784.USD","SCHM","LU2237438978.USD","HK0000306685.HKD","LU1868836591.USD","SG9999004303.SGD","EGGY","LU2505996509.AUD","LU1934455863.HKD","SG9999015945.SGD","LU0061475181.USD","BK4533","LU1914381329.SGD","LU1791710400.SGD","SG9999014575.USD","LU2360107168.USD","LU0672654240.SGD","BK4116","LU0323239441.USD","IE00BJJMRY28.SGD","LU0107464264.USD","XLK","SNDQ","LU1400636574.HKD","LU0868494708.USD","LU1670756490.USD","IE00BJLML261.HKD","LU2168564065.EUR","TSII","LU2543165471.USD","NVDB","LU2552382132.HKD","NVDQ","LU0708995401.HKD","IE0034235295.USD","LU0077335932.USD","SPTE","LU2237443549.SGD","LU2430703251.USD","TSLT","IE00BQXX3D17.EUR","LU0256863902.USD","LU1989772840.SGD","LU0417517546.SGD","LU1989772923.USD","LU0353189763.USD","LU0347712357.USD","LU0057025933.USD","LU2168564222.USD","LU1400636491.USD","SNVD.UK","IE00B3S45H60.SGD","LU0109392836.USD","NJUL","LU2168564149.EUR","LU1400636657.SGD","LU2168564495.EUR","TSLI","LU0957791311.USD","LU2452424414.USD","SG9999001424.SGD","TSLS","NJAN","LU0965509010.AUD","LU2462591350.SGD","BK4141","NVDY","BK4560","TRFK","LU1119994496.HKD","BK4567","SGXZ81514606.USD","LU2065171402.SGD","LU2089284900.SGD","LU0006306889.USD","LU1066051498.USD","LU1868836757.USD","LU0942090050.USD","IE00B3SWFQ91.USD","IE00BFSS8Q28.SGD","SGXZ23171101.USD","STX","EFIV","LU2087625088.SGD","LU0310800379.SGD","LU1623119135.USD","BK4587","BK4588","BK4007","IE0005OL40V9.USD","LU1923622614.USD","LU2028103732.USD","LU0965508806.USD","LU0082616367.USD","BK4534","IE000W1ABFV2.USD","LU1861558580.USD","IE00BZ1G4Q59.USD","LU1069347547.HKD","AGIO","LU2023250504.SGD","LU2125909593.SGD","ESUM","LU1496350502.SGD","IE000ITXATA3.USD","XDAT","BK4585","LU0072461881.USD","LU0133085943.USD","BK4170","BK4512","IE0009G5SDU7.USD","03455","CLOU","IE00BMPRXR70.SGD","LU1645745479.HKD","LU0211327993.USD","IE00BYXW3230.USD","LU0048584097.USD","LU0528227936.USD","TSLQ","LU0289961442.SGD","LU2100268510.USD","NETX","LU2430703095.HKD","LU0124676726.USD","LU0061474705.USD","HK0000914660.USD","IE00BMPRXQ63.HKD","LU2087621335.USD","LU2272731782.SGD","NVD2.UK","TSL","IE00B19Z9Z06.USD","USD","LU1235294995.USD","LU2125909759.SGD","TEK","BK4613","LU0138981039.USD","LU0719512351.SGD","WDCX","IE000KEQY171.SGD","LU1066051811.HKD","LU0266013472.USD","LU0310799852.SGD","LU1629891620.HKD","IE00BQXX3C00.GBP","LU2471134879.HKD","LU2461242641.AUD","LU0265550359.USD","07266","LU2999663052.SGD","LU0345768740.USD","LU0316494557.USD","JGRO","LU1244550577.SGD","LU1429558221.USD","LU2552382215.SGD","LU1720051017.SGD","TSLP","CLSE","LU2361044949.HKD","09834","SNDC","LU0210533765.USD","LU1670627923.USD","LU0251132253.USD","BK4555","LU1880398471.USD","FAI","TTEQ","VT","IE0001KFT4U8.USD","LU0683600562.USD","LU2360106780.USD","IDRV","LU2211815571.USD","LU1804176565.USD","QQQX","HK0000304805.HKD","LU1861127337.USD","LU2322448791.USD","BK4547","CHAT","VGT","LU2746668461.USD","LU1917777945.USD","LU1127390331.HKD","LU1496350171.SGD","LU0444973449.USD","LU2433249047.HKD","LU0006061336.USD","LU2247934214.USD","LU2322448957.HKD","NVIW.SI","USXF","07261","LU2954938101.SGD","LU2271345857.HKD","ILDR","TQQY","09086","LU2237443622.USD","LU1046421795.USD","AIPI","LU0689626769.HKD","LU1868837300.USD","LU1037948541.HKD","SG9999002224.SGD","LU2191332357.HKD","SNDU",".IXIC","NVDD","QQQM","LU2286300806.USD","07366","LU2462591277.SGD","LU1280957306.USD","LU2756315664.SGD","LU1923622291.USD","LU2249611893.SGD","LU2265009873.SGD","SGXZ51526630.SGD","BK4607","HK0000320264.USD","LU2430703178.SGD","CNEQ","LU1145028129.USD","LU0342679015.USD","SMHX","BK4511","LIT","NOCT","SOXY","LU2089283258.USD","LU2097344431.USD","LU1839511570.USD","LU0072462426.USD","LU0011850046.USD","LU0323591593.USD","BK4549","SMOG","LU0724617625.USD","LU1951200564.SGD","LU0080751232.USD","LU0267386448.USD","LU2458330243.SGD","LU0788109477.HKD","LU0158827781.USD","SG9999018865.SGD","LU0353189680.USD","LU0354030438.USD","LU2361044865.SGD","GB00BDT5M118.USD","LU0203202063.USD","LU0511384066.AUD","SG9999014914.USD","SG9999018857.SGD","LU0203347892.USD","NVII","PTF","LU1815333072.USD","IE00B775H168.HKD","LU1718418525.SGD","LU1035775433.USD","LU2750360641.GBP","LU2357305700.SGD","07568","SCHA","LU0345769128.USD","BK4581","LU1244550494.USD","LU0238689110.USD","SNPE","LU0127658192.USD","LU0203201768.USD","LU2462157665.USD","LU0154236417.USD","QQQG","LU0096362180.USD","LU2063271972.USD","QID","SG9999014906.USD","LU1066051225.USD","LU0215105999.USD","TSDD","LU0323240290.USD","LU0274383776.USD","SHOC","LU0889565833.HKD","LU0096364046.USD","TQQQ","FTEC","LU1551013342.USD","NVD","BK4548","LU0823434583.USD","LU2394011477.USD","LU2381873111.SGD","LU1116320737.USD","LU1674673428.USD","07766","LU0823421333.USD","IE00BK4W5M84.HKD","LU2272731865.HKD","IE00BKVL7J92.USD","COWG","BK4598","QLD","TSLL","IE00B1BXHZ80.USD","LU0963586101.USD","LU2106854487.HKD","LU2506951792.HKD","QQQ","LU0787776722.HKD","LU1699723380.USD","BK4139","LU2065171311.SGD","LU2236285917.USD","LU1923623000.USD","LU0557290698.USD","SNDK","LU1983260115.SGD","LU0234570918.USD","SG9999015986.USD","LU2237443382.USD","LU0882574139.USD","LU0210536198.USD","LU1548497426.USD","LU0345768153.USD","03034","AIFD","LU1242518857.USD","SGXZ31699556.SGD","FDTX","LU1935043536.SGD","IE00BQXX3F31.USD","IE00B7KXQ091.USD","LU2089985449.USD","LU0823414551.USD","LU1366192091.USD","LU2473716301.USD","NVDL","2NVD.UK","LFGY","LU0187121727.USD","LU1989764748.USD","LU2108987350.USD","TESL","03086","METV","SQQQ","LU0985320562.USD","TSLR","IE00BK4W5L77.USD","LU2083900584.USD","BK4550","NET","LU1992135399.USD","07522","LU0345770993.USD","IE00BSNM7G36.USD","IE00B775SV38.USD","LU1814569148.SGD","TLA","LU2403377893.USD","SMH","LU0056508442.USD","AGOX","LU1935042215.USD","LU2750360997.AUD","BK4099","LU0494093205.USD","LU0320765059.SGD","LU2458330169.SGD","LU2756315318.SGD","LU1951198990.SGD","LU2092937148.SGD","LU0308772762.SGD","3NVD.UK","LU0820561818.USD","LU1935042991.SGD","LU1778281490.HKD","LU1935042488.USD","LU0276348264.USD","BK4608","LU0106261372.USD","IE0004091025.USD","LU2054465674.USD","LU0868494617.USD","LU0174119429.USD","LU2237957902.USD","HK0000320223.HKD","TSLY","LU2272731600.USD","SOXX","LU0640476718.USD","CRNX","LU1880398554.USD","ROM","NVDG","BK4532","LU0029864427.USD","LU0708994859.HKD","NULC","BK4592","HXC","LU2471134796.USD","QDEC","LU1323610961.USD","LU3102509885.SGD","LU1064131342.USD","LU2244417387.USD","LU0390134368.USD","LU1366333091.USD","LU1868836914.USD","LU1551013425.SGD","HK0000304797.USD","LU0198837287.USD","HK0000819398.USD","LU1803068979.SGD","LU2471134523.USD","LU1721428933.USD","LU1244550221.USD","LU2420271590.USD","IETC","LU2471134952.CNY","LU0472753341.HKD","BK4614","IE00BKDWB100.SGD","NAPR","SG9999014898.SGD","LU1988902786.USD","LU2417539215.USD","SG9999000418.SGD","LU2237443465.HKD","LU2290526834.HKD","LU1935043023.USD","LU1823568750.SGD","LU0345770308.USD","LU1934455194.USD","LU2111349929.HKD","LU0256863811.USD","LU1934455277.USD","TSLO","LU2592432038.USD","LU0211328371.USD","LU2491050154.USD","SG9999015358.SGD","SG9999014880.SGD","IE00B894F039.SGD","LU2896262040.SGD","LU1852331112.SGD","LU0820561909.HKD","IE000Q6AESB8.SGD","SGXZ99366536.SGD","BK4527","FCUS","LU2237957811.SGD","WDC","LU1316542783.SGD","LU0289960550.SGD","LU1261432733.SGD","LU2168563687.JPY","LU0094547139.USD","LU0943347566.SGD","SG9999014559.SGD","IE0034235303.USD","LU0348723411.USD","LU0109391861.USD","CMPS","ARTY","LU2413666426.HKD","LU2237443895.HKD","LU0128525929.USD","IE000YTNTUN2.SGD","LU2463028550.USD","LU1674673691.USD","LU0162691827.USD","NVDU","LU2326559502.SGD","PSQ","LU1066053197.SGD","TSLA","SOXQ","IE00BDRTCR15.USD","LU1267930490.SGD","LU1974910355.USD","TYLG","LU1116320901.HKD","LU2491049909.HKD","IE0004445015.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139021636","title":"COMPASS Pathways股價盤前大漲8.6%，抑鬱症療法後期試驗數據積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1139021636","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139021636?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 18:42","pubTimestamp":1783420930,"startTime":"0","endTime":"0","summary":"在公布其抑郁症治疗药物的积极后期试验数据后，COMPASS Pathways plc的股价在盘前交易时段飙升了8.6%。这一显著涨幅反映了市场对该药物研发进展的乐观情绪，以及其未来商业潜力的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104642085","title":"COMPASS Pathways公布第二階段三期試驗六個月數據，證實快速且持久的療效特徵","url":"https://stock-news.laohu8.com/highlight/detail?id=1104642085","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104642085?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 18:33","pubTimestamp":1783420411,"startTime":"0","endTime":"0","summary":"COMPASS Pathways plc宣布，其第二阶段三期临床试验的六个月数据已公布，结果证实了其疗法具备快速起效且疗效持久的特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175403731","title":"COMPASS Pathways旗下COMP360持續展現良好耐受性與安全性，未發現新安全風險","url":"https://stock-news.laohu8.com/highlight/detail?id=1175403731","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175403731?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 18:32","pubTimestamp":1783420321,"startTime":"0","endTime":"0","summary":"COMPASS Pathways plc 公布的数据表明，其研究性疗法COMP360继续展现出良好的耐受性与安全性特征，且未出现新的安全性发现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}